Treatment of chronic diseases such as multiple sclerosis (MS) will likely be guided in the near future by the genetic makeup of individual patients. Called “genetic-based optimization,” this genetic treatment approach will enable physicians to choose a particular MS drug and dosage based on each individual’s unique DNA.
Copaxone and Genes: What MS Research Shows
A study published in August 2007 was performed in Israel at Rappaport Faculty of Medicine and Research Institute, Technion and Carmel Medical Center. Researchers in the study analyzed the DNA from individuals who were taking a medication used in an MS treatment called glatiramer acetate (Copaxone).
The scientist tested 27 different genes and made comparisons to the clinical effect of Coaxone. They ultimately discovered two specific genes that had a positive correlation between Copaxone and an improved clinical response. In other words, individuals with a specific code in their DNA would respond better to Copaxone.
Future MS Research May Focus on Genetic Treatment
The current method of choosing a medication is, at best, often a process of trial and error. However, if physicians can determine the presence of certain genes in the DNA of a patient, they will then be able to tailor MS treatment – medication and dosage choices – for maximum benefit. This is likely the wave of the future for MS research (and medication), enabling highly effective matching between patients and medications while also decreasing side effects.
Source: "Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis reveals a drug-response markers,” I. Grossman, Pharmacogenetics and Genomics, 2007 Aug;17(8):657-666.
See Related Articles
Studies show a new treatment for Multiple Sclerosis (MS) may be on the horizon. To read more about the drug shown to reduce the progression of MS, see New MS Drug Shows Promising Results in Early Tests.
See MS Treatment: Advances in MS Therapy for more information about currently approved Multiple Sclerosis (MS) medications and therapies.
